Immune checkpoint inhibitors are a type of cancer immunotherapy that can cause inflammatory side effects similar to rheumatic diseases. In this lecture, Laura Cappelli, MD, focuses on the diagnosis and management of rheumatic immune-related adverse events that occur due to immune checkpoint inhibitor therapy. The management of patients with preexisting autoimmune disease and cancer who are being treated with immune checkpoint inhibitors is also discussed.
View the lecture summary
In this lecture, Sangeeta Sule, MD, PhD, focuses on “pediatric rheumatology things to know” for the adult fellow in training. With the shortage of pediatric rheumatologists around the United States, it is important for adult rheumatologists to be familiar with the most common pediatric rheumatologic diseases.
Anti-resorptive therapies are highly efficacious in the management of osteoporosis, and there are many important considerations regarding the selection of oral, intravenous, or subcutaneous treatment options. Consideration should be given to the duration of therapy and should be individualized to each patient based on the patient’s co-morbidities, fall risk, bone density (T-scores by DXA scan), and fracture history. Appropriate institution of a bisphosphonate holiday should be implemented with ongoing careful consideration given to duration of this drug holiday and resumption of treatment.
The purpose of this presentation is to improve the attendee's ability to critically appraise clinical rheumatology studies. Bryant England, MD, PhD, will cover the principles of establishing causality and the most frequent types of clinical study designs used in rheumatology. Attendees will be asked to apply these study designs to different clinical questions throughout the presentation.
View the lecture summary
Daniel Solomon, MD, MPH, reviews the most important clinical science papers in rheumatology of 2019. He describes studies across the spectrum of rheumatic diseases, identifying their key findings and implications for practice.
In this presentation, Vasileios Kyttaris, MD, covers late phase trials of medication in SLE. This presentation examines the underlying pathophysiology of the disease and trial design.
View the lecture summary
This talk reviews the evaluation and management of idiopathic inflammatory myopathies. Treatment algorithms are discussed through a case-based presentation. Promising treatments on the horizon are also highlighted, especially in dermatomyositis.
This lecture is an overview of the current knowledge of rheumatic disease activity in pregnancy and pregnancy outcomes in those with a variety of rheumatic diseases. In addition, rheumatic disease medication safety in pregnancy will be presented. Appropriate, evidence-based contraception in those with rheumatic diseases will also be addressed.
View the lecture summary
This talk will review severe emergencies manifesting in patients with scleroderma. Recognizing early signs and symptoms of critical digital ischemia and scleroderma renal crisis is critical to minimize significant morbidity and in some cases mortality. Intestinal pseudo-obstruction can develop in advanced scleroderma gastro-intestinal disease and is associated with poor outcomes. Surgery may not be necessary, but prolonged gut rest and assertive nutrition (e.g. TPN) is often required.
As rheumatologists, it is important for us to try and understand the rapidly expanding body of literature surrounding COVID-19 and the use of anti-rheumatic drugs. Investigations into the role of these medications impacts both the pandemic as well as our patients. During this talk, Dr. Anisha Dua and Dr. Michael Putnam briefly address some of the theoretical rationale behind the use of rheumatic drugs in the treatment of COVID-19 patients, and delve into the available data to date, with a focus on hydroxychloroquine/chloroquine and IL-6 inhibition.
View the lecture summary
This talk reviews the pathogenesis and clinical manifestations of antiphospholipid syndrome (APS). Cases are used to highlight the complexities and nuances of treatment decisions in the management of patients with APS.
View the lecture summary
This lecture examines the benefits and limitations of the 2016 ACR/EULAR classification criteria for Sjögren’s disease, explains the value of ultrasound assessment of salivary glands when Sjögren’s disease is suspected, and demonstrates extra-glandular feature of Sjögren’s disease.
View the lecture summary
RA 2020 reviews therapeutics in rheumatoid arthritis highlighting studies on methotrexate, biologics including withdrawal trials and toxicities, jak inhibitors including efficacy and adverse events including dvt and pulmonary emboli. The talk includes recently presented data at the 2019 annual meeting and new publications.
View the lecture summary
Systemic sclerosis involves the gastrointestinal tract in over 90% of patients, but the presentation of clinical symptoms in patients varies widely. In this talk we will review the clinical and serologic risk factors for severe gastrointestinal involvement in systemic sclerosis, consider the data related to pathogenesis, and treatments. Finally we will focus on a couple of patient cases and go over the approach to evaluation and management.
View the lecture summary
Dr. Michelle Petri, Johns Hopkins University School of Medicine, reviews the epidemiology and pathogenesis of lupus, treatment, and co-morbidity. Dr. Petri also reviews HCQ and COVID-19.
View the lecture summary
This talk reviews the mimics of axial spondyloarthritis in addition to some of the therapeutic complexities in patients with extra-musculoskeletal manifestations. The learner will be able to identify the axial spondyloarthritis differential diagnosis and understand the sensitivity/specificity of various features of disease.
View the lecture summary
This lecture reviews background on GPA and MPA vasculitis with a focus on discussing therapeutic options for inducing and maintaining remission in patients with ANCA vasculitis. Discussion of recent trials including PEXIVAS, MAINRITSAN and other major trials that helped to inform the preliminary ACR/VF Guideline for managing severe AAV are reviewed along with potential new targets which have been identified through increased understanding of the pathophysiology of AAV.
View the lecture summary